<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00622180</url>
  </required_header>
  <id_info>
    <org_study_id>IRB file number 122007-003</org_study_id>
    <secondary_id>122007-003</secondary_id>
    <nct_id>NCT00622180</nct_id>
  </id_info>
  <brief_title>The Efficacy of Hand Narrow-Band Ultraviolet B (NBUVB) Versus Excilite Treatment in Vitiligo After Minigrafting on the Dorsal Hands</brief_title>
  <official_title>The Efficacy of Hand-Foot Narrow-Band Ultraviolet B (UVB) Versus Focal 308-nm Treatment in Inducing Repigmentation of Vitiligo After Minigrafting on the Dorsal Hands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess over a 25-week period the efficacy of hand-foot narrow-band ultraviolet B light
      versus focal 308-nm light treatment in inducing the return of pigment in vitiligo after skin
      minigraft transplants to the backs of the hands in patients with light brown to black skin.
      Subject will undergo treatment for 13 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective investigator-blinded study involving 13 adult male and female subjects with
      vitiligo on the backs of both hands. Punch minigrafting will be performed on both hands
      taking skin from the thighs and/or buttocks. Light treatments will be administered starting
      at week one after grafting. One hand will receive narrow-band ultraviolet B light and the
      other will receive focal 308-nm light treatments. Light treatments will be administered 3
      times per week for 12 weeks. A long term follow-up visit will be completed at week 25. The
      investigator will evaluate the subjects at week 4, 7, 13 and 25 in addition to screening and
      baseline evaluations/procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Repigmentation of Target Lesion</measure>
    <time_frame>25 weeks</time_frame>
    <description>This is measured using photography and Scion software calculations.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Daavlin Right vs. Excilite Left</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Right hand treated with narrow-band UVB light and left hand treated with focal 308nm light.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Excilite Right vs. Daavlin Left</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Right hand treated with focal 308-nm light and left hand treated with narrow-band UVB light</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NBUVB</intervention_name>
    <description>NBUVB hand foot box</description>
    <arm_group_label>Daavlin Right vs. Excilite Left</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Monochromacitc Excimer light</intervention_name>
    <description>Treatment with Monochromacitc Excimer light</description>
    <arm_group_label>Excilite Right vs. Daavlin Left</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female subjects 18 years of age or older

          -  skin type III-VI

          -  vitiligo on both dorsal hands

          -  history of stable vitiligo ( no new lesions and no more than 10% enlargement of
             existing lesions) for six months with an absence of Kebner phenomenon (new lesions
             appearing after trauma to the skin)

          -  refractory to topical steroids and immunomodulators

        Exclusion Criteria:

          -  pregnant and/or breast-feeding females

          -  history of skin cancer

          -  history of taking photosensitizing medications

          -  history of recent phototherapy (light therapy) or topical medications within one month
             prior to enrollment

          -  history of organ transplantation

          -  history of failed vitiligo skin transplantation

          -  history of segmental vitiligo

          -  history of 12 or more continuous light treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Pandya, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center at Dallas - Department of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 23, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <results_first_submitted>August 30, 2013</results_first_submitted>
  <results_first_submitted_qc>November 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2019</results_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitiligo</keyword>
  <keyword>Light treatment for vitiligo</keyword>
  <keyword>Excilite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>It was our hope to enroll 26 Participants but only 13 was enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Daavlin Right vs. Excilite Left</title>
          <description>Right hand treated with narrow-band UVB light and left hand treated with focal 308nm light.</description>
        </group>
        <group group_id="P2">
          <title>Excilite Right vs. Daavlin Left</title>
          <description>Right hand treated with focal 308-nm light and left hand treated with narrow-band UVB light</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>The Efficacy of Hand NBUVB Vs. Excilite Treatment in Vitiligo</title>
          <description>Light therapy with the NBUVB hand-foot box to one hand and the Excilite to the other hand three times a week on non-consecutive days for a total of 12 weeks. The light will be dosed as follows: starting dose for NBUVB will be 200 mJ/cm2 with subsequent dose increases of 15% per treatment as tolerated. For the Excilite device, the starting dose will be 200 mJ with subsequent dose increases of 50 mJ per treatment as tolerated.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Repigmentation of Target Lesion</title>
        <description>This is measured using photography and Scion software calculations.</description>
        <time_frame>25 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NBUVB</title>
            <description>Treatment with NBUVB</description>
          </group>
          <group group_id="O2">
            <title>Monochromatic Excimer Light</title>
            <description>One hand treated with monochromatic excimer light</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Repigmentation of Target Lesion</title>
          <description>This is measured using photography and Scion software calculations.</description>
          <units>percentage of repigmentation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.35"/>
                    <measurement group_id="O2" value="0.17" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Daavlin vs. Excilite</title>
          <description>Right hand treated with narrow-band UVB light and left hand treated with focal 308nm light.
Daavlin Spectra UVB Hand/Foot Box : Narrow-band ultraviolet B hand box
Excilite Focal 308-nm light : Excilite Focal 308-nm light</description>
        </group>
        <group group_id="E2">
          <title>Excilite vs. Daavlin</title>
          <description>Right hand treated with focal 308-nm light and left hand treated with narrow-band UVB light
Excilite Focal 308-nm light : Excilite Focal 308-nm light
Daavlin Spectra UVB Hand/Foot Box : Narrow-band ultraviolet B hand box</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amit Pandya, M.D.</name_or_title>
      <organization>UT Southwestern Medical Center at Dallas</organization>
      <phone>214-645-8300</phone>
      <email>amit.pandya@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

